Rhino-conjunctivitis Quality of Life Questionnaire
(RQoL)
In most studies, the study participants were asked to fill a
questionnaire before and after the intervention to evaluate the efficacy
of treatment. The questions pertained a variation of outcomes including
sleep impairment, usual daily activity limitations, emotional functions,
symptoms meaningful change and an overall score, which reflected the
evaluation of the overall efficacy of the treatment. Four studies with
992 randomized patients provided enough data on an overall score of RQoL
that allowed for a quantitative synthesis. The overall score was
measured in a 5-point scale in 3 studies11, 14, 15 and
in a 7-point scale in 1 study16. In all 4 studies, the
respective score ranged from low to high score values indicating
excellent to poor effectiveness of treatment respectively. Omalizumab
statistically significantly reduced the RQoL by a summary standardized
mean difference of -0.45 (95% CI, -0.57, -0.34; p<0.001;
I2 = 0%) (Figure 5).